# Prelude Therapeutics (stock symbol: PRLD) Logo in transparent PNG and SVG formats

## Prelude Therapeutics Logo large

### Prelude Therapeutics Logo large Download PNG (74.96 KB)

![Prelude Therapeutics Logo large Download PNG (74.96 KB)](/img/orig/PRLD_BIG-5bb9dc3d.png)

### Prelude Therapeutics Logo large Download SVG (10.68 KB)

![Prelude Therapeutics Logo large Download SVG (10.68 KB)](/img/orig/PRLD_BIG-9762c053.svg)

## Prelude Therapeutics Logo icon format

### Prelude Therapeutics Logo icon format Download PNG (179.03 KB)

![Prelude Therapeutics Logo icon format Download PNG (179.03 KB)](/img/orig/PRLD-c0b9e864.png)

### Prelude Therapeutics Logo icon format Download SVG (8.5 KB)

![Prelude Therapeutics Logo icon format Download SVG (8.5 KB)](/img/orig/PRLD-ef476658.svg)

## Prelude Therapeutics Logo large for dark backgrounds

### Prelude Therapeutics Logo large for dark backgrounds Download PNG (44.81 KB)

![Prelude Therapeutics Logo large for dark backgrounds Download PNG (44.81 KB)](/img/orig/PRLD_BIG.D-489fe184.png)

### Prelude Therapeutics Logo large for dark backgrounds Download SVG (10.65 KB)

![Prelude Therapeutics Logo large for dark backgrounds Download SVG (10.65 KB)](/img/orig/PRLD_BIG.D-f177c537.svg)

## Prelude Therapeutics Logo icon format for dark backgrounds

### Prelude Therapeutics Logo icon format for dark backgrounds Download PNG (104.76 KB)

![Prelude Therapeutics Logo icon format for dark backgrounds Download PNG (104.76 KB)](/img/orig/PRLD.D-2102eed3.png)

### Prelude Therapeutics Logo icon format for dark backgrounds Download SVG (8.48 KB)

![Prelude Therapeutics Logo icon format for dark backgrounds Download SVG (8.48 KB)](/img/orig/PRLD.D-350b39d1.svg)

## About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

1. Website domain: preludetx.com
2. Employees: 120
3. Marketcap: $0.30 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
